factor

(redirected from factor VIII activity)
Also found in: Dictionary, Thesaurus, Medical, Legal, Encyclopedia.
Related to factor VIII activity: Factor VIII deficiency

Factor

A financial institution that buys a firm's accounts receivable and collects the accounts.

Factor

A third party that buys a firm's accounts receivable. If a firm is not confident in its ability to collect on its credit sales, it may sell the right to receive payment to the factor at a discount. The factor then assumes the credit risk associated with the accounts receivable. This provides the firm immediate access to working capital, which is important, especially if the firm has a cash flow problem. The price of factoring is determined by the creditworthiness of the firm's customer, not of the firm itself. It is also known as accounts receivable financing.

factor

A firm that purchases accounts receivable from another firm at a discount. The purchasing firm then attempts to collect the receivables.

factor

To sell accounts receivable to another party at a discount from face value. Thus, a firm in need of cash to pay down short-term debt may decide to factor its accounts receivable to another firm.

factor

  1. a firm that purchases TRADE DEBTS from client firms. See FACTORING.
  2. a firm that buys in bulk and performs a WHOLESALING function.
  3. an input (for example raw material, labour, capital) which is used to produce a good or provide a service.

factor

  1. 1a FACTOR INPUT that is used in production (see NATURAL RESOURCES, LABOUR, CAPITAL).
  2. a business that buys in bulk and performs a WHOLESALING function.
  3. a business that buys trade debts from client firms (at some agreed price below the nominal value of the debts) and then arranges to recover them for itself. See FACTOR MARKET, FACTORING.
References in periodicals archive ?
Factor VIII Activity Level Changes Continued to be Expression Level Dependent, Slowed in Year Three, and Appears to be Approaching Plateau
Measurement of factor VIII activity of B-domain deleted recombinant factor VIII.
Table 1 Genetic causes of venous thrombosis Common Activated protein C resistance (APCR)/ Factor V Leiden Prothrombin 20210 mutation Methylenetetrahydrofolate reductase gene mutation Increased factor VIII activity Rare Deficiencies of antithrombin and proteins C and S Very Rare Dysfibrinogenemia Table 2 Acquired conditions affecting functional hypercoagulability test results Antithrombin Decreased in heparin use, recent thrombosis, liver disease, DIC, (1) nephrotic syndrome APCR First generation assays: High factor VIII level, LA, (2) acute phase response Second generation assays: Strong LA, (2) pregnancy Factor VIII Elevated in acute phase reaction; falsely decreased in the presence of LA (2) Homocysteine Elevated in recent thrombosis.
The product includes a recombinant analogue of porcine FVIII that allows physicians to manage the treatment's efficacy and safety by measuring factor VIII activity levels in addition to clinical evaluations.
Clotting factor VIII activity was below the detection limit (<5 IU/dL; reference interval, 70-150 IU/dL), and the activity of factor XII was slightly reduced (53 IU/dL, reference interval, 70-150 IU/dL).
The analyst cites Latin America seasonal ordering patterns among the likely culprits, adding that the next potential catalyst for BioMarin - the June release of Phase I/II Study of Valrox - could also see a "downward trend of Factor VIII activity levels." Nash keeps his Buy rating on the shares longer term, stating that BioMarin's R&D competencies and a "strong sales force in Orphan markets will continue to provide strong revenue growth and durable barriers to entry".
According to the company, OBIZUR is the first recombinant porcine FVIII treatment approved for AHA that allows physicians to manage the treatment's efficacy and safety by measuring factor VIII activity levels in addition to clinical assessments.
For minor bleeding episodes, factor VIII activity should be increased to 30%-50% of normal; for more-severe bleeding episodes, factor VIII activity should be increased to 50%-70%.
The patients were treated with an initial dose of OBI-1 (200 units per kilogram), followed by additional doses based on their personal profiles, including clinical evaluations and target factor VIII activity levels.
Factor VIII activity as measured by an amidolytic assay compared with one-stage clotting assay.
Feiba 500 u / 1000u powder and solvent for solution for injection coagulante complex with factor viii activity antiinhibidora.